Comparison of the safety of brivaracetam at various doses among patients with epilepsy: A network meta‑analysis of randomized controlled trials

  • Authors:
    • Ying Meng
    • Jiahuan Wu
    • Jianxin Shi
    • Wenyu Weng
    • Zhikun Zhou
  • View Affiliations

  • Published online on: October 2, 2020     https://doi.org/10.3892/etm.2020.9262
  • Article Number: 133
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to compare the safety of brivaracetam (BRV) at various doses among patients with epilepsy through a network meta‑analysis. Randomized controlled trials (RCTs) were retrieved from different databases, which were then pooled for a network analysis for calculating the odds ratios (ORs), together with the corresponding 95% confidence intervals (CIs) and surface under the cumulative ranking curve (SUCRA). A total of 9 RCTs were included in the final analysis. Compared with placebo, BRV at a dose of 50 mg daily led to a markedly increased risk of nervous system disorders (OR, 0.62; 95% CI, 0.43‑0.90; P=0.01) and evidently increased the risk of psychiatric disorders (OR, 0.16; 95% CI, 0.04‑0.64; P=0.022). However, BRV treatment was not associated with a statistically significant change in the prevalence of infectious diseases. SUCRA analysis suggested that treatment with BRV at 50 mg/day posed the highest risk of nervous system disorders and psychiatric disorders compared with placebo or other doses of BRV. In conclusion, BRV treatment at a dose of 50 mg/day may increase the risk of nervous system diseases and psychosis disorders compared with the placebo group. However, more high‑quality clinical studies are warranted to validate these results.
View Figures
View References

Related Articles

Journal Cover

December-2020
Volume 20 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Meng Y, Wu J, Shi J, Weng W and Zhou Z: Comparison of the safety of brivaracetam at various doses among patients with epilepsy: A network meta‑analysis of randomized controlled trials. Exp Ther Med 20: 133, 2020
APA
Meng, Y., Wu, J., Shi, J., Weng, W., & Zhou, Z. (2020). Comparison of the safety of brivaracetam at various doses among patients with epilepsy: A network meta‑analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 20, 133. https://doi.org/10.3892/etm.2020.9262
MLA
Meng, Y., Wu, J., Shi, J., Weng, W., Zhou, Z."Comparison of the safety of brivaracetam at various doses among patients with epilepsy: A network meta‑analysis of randomized controlled trials". Experimental and Therapeutic Medicine 20.6 (2020): 133.
Chicago
Meng, Y., Wu, J., Shi, J., Weng, W., Zhou, Z."Comparison of the safety of brivaracetam at various doses among patients with epilepsy: A network meta‑analysis of randomized controlled trials". Experimental and Therapeutic Medicine 20, no. 6 (2020): 133. https://doi.org/10.3892/etm.2020.9262